2019
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools
Foldi J, O'Meara T, Marczyk M, Sanft T, Silber A, Pusztai L. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools. Journal Of Clinical Oncology 2019, 37: jco.18.01933. PMID: 30943126, DOI: 10.1200/jco.18.01933.Peer-Reviewed Original Research
2016
Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer
Bobowicz M, Skrzypski M, Czapiewski P, Marczyk M, Maciejewska A, Jankowski M, Szulgo-Paczkowska A, Zegarski W, Pawłowski R, Polańska J, Biernat W, Jaśkiewicz J, Jassem J. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clinical & Experimental Metastasis 2016, 33: 765-773. PMID: 27485175, PMCID: PMC5110606, DOI: 10.1007/s10585-016-9810-1.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalColon cancerMMR statusShorter distant metastasis-free survivalEarly-stage colon cancerMiR-592 expressionGroup of patientsMetastasis-free survivalExpression signaturesCox univariate analysisStage colon cancerNormal colon mucosa samplesColon mucosa samplesMiRNA expression signaturesAdjuvant chemotherapyDistant relapseMiRNA expressionDistant metastasisMiR-423-5pCC patientsPrognostic significancePrognostic valueSuch therapyUnivariate analysisHigh risk